Abstract:Abstract Background Porcine circovirus type 2 (PCV2) is the causative agent of postweaning multisystemic wasting syndrome, and is associated with a number of other diseases. PCV2 is widely distributed in most developed swine industries, and is a severe economic burden. With an eye to developing an effective, safe, and convenient vaccine against PCV2-associated diseases, we have constructed a recombinant Bacillus subtilis strain ( B. subtilis -Cap) that expresses the PCV2 capsid protein (Cap). Methods Electroporation of a plasmid shuttle vector encoding the PCV2 Cap sequence was use to transform Bacillus subtilis . Flow cytometry was used to evaluate in vitro bone marrow derived dendritic cell (BM-DC) maturation and T cell proliferation induced by B. subtilis -Cap. Orally inoculated piglets were used for in vivo experiments; ELISA and western blotting were used to evaluate B. subtilis -Cap induced PCV2-specific IgA and IgG levels, as well as the secretion of cytokines and the expression of Toll-like receptor 2 (TLR2) and Toll-like receptor 9 (TLR9). Results We evaluated the immune response to B. subtilis -Cap in vitro using mouse BM-DCs and in vivo using neonatal piglets orally inoculated with B. subtilis -Cap. Our results showed that the recombinant B. subtilis -Cap activated BM-DCs, significantly increased co-stimulatory molecules (CD40 and CD80) and major histocompatibility complex II, and induced allogenic T cells proliferation. Piglets immunized with B. subtilis -Cap had elevated levels of PCV2-specific IgA in the mucosal tissues of the digestive and respiratory tract, and PCV2-specific IgG in serum ( P < 0.05 or P < 0.01). Ileal immunocompetent cells, such as the IgA-secreting cells ( P < 0.01), intestinal intraepithelial lymphocytes (IELs) ( P < 0.01), CD3 + T lymphocytes ( P < 0.01) and CD4 + T lymphocytes ( P < 0.01) increased significantly in the B. subtilis -Cap immunized piglets. Additionally, B. subtilis -Cap inoculation resulted in increased the expression of TLR2 and TLR9 ( P < 0.01), and induced the secretion of cytokines IL-1β, IL-6, interferon-γ, and β-defensin 2 ( P < 0.01). Conclusions We constructed a prototype PCV2 vaccine that can be administered orally and elicits a more robust humoral and cellular immunity than inactivated PCV2. B. subtilis -Cap is a promising vaccine candidate that is safe, convenient, and inexpensive. Further in vivo research is needed to determine its full range of efficacy in pigs. Graphical abstract

Immune Responses Induced by Recombinant Bacillus Subtilis Expressing the Spike Protein of Transmissible Gastroenteritis Virus in Pigs

[Construction of Recombinant Lactococcus Lactis Expressing Porcine Transmissible Gastroenteritis Spike Glycoprotein and Analysis of Immunogenicity].

Immunization with Excreted–secreted Antigens Reduces Tissue Cyst Formation in Pigs

Efficacy and Immunogenicity of Recombinant Swinepox Virus Expressing the A Epitope of the Tgev S Protein

Evaluation on the Efficacy and Immunogenicity of Recombinant DNA Plasmids Expressing Spike Genes from Porcine Transmissible Gastroenteritis Virus and Porcine Epidemic Diarrhea Virus

Designing a Candidate Multi-Epitope Vaccine against Transmissible Gastroenteritis Virus Based on Immunoinformatic and Molecular Dynamics

CpG DNA facilitate the inactivated transmissible gastroenteritis virus in enhancing the local and systemic immune response of pigs via oral administration

Construction of an Oral Vaccine for Transmissible Gastroenteritis Virus Based on the Tgev N Gene Expressed in an Attenuated Salmonella Typhimurium Vector

Construction and Characterization of Porcine Single-Chain Fragment Variable Antibodies That Neutralize Transmissible Gastroenteritis Virus in Vitro

The N-Terminal Domain of Spike Protein Is Not the Enteric Tropism Determinant for Transmissible Gastroenteritis Virus in Piglets

Mucosal immune responses induced by oral administration recombinant Bacillus subtilis expressing the COE antigen of PEDV in newborn piglets.

Porcine IL-12 plasmid as an adjuvant improves the cellular and humoral immune responses of DNA vaccine targeting transmissible gastroenteritis virus spike gene in a mouse model

Oral Immunization of Mice with Recombinant Lactococcus Lactis Expressing Porcine Transmissible Gastroenteritis Virus Spike Glycoprotein

Immune Responses Induced by Recombinant Bacillus Subtilis Expressing the PEDV Spike Protein Targeted at Microfold Cells

Progress in Genetically Engineered Vaccines for Porcine Transmissible Gastroenteritis Virus

Immune response in piglets orally immunized with recombinant Bacillus subtilis expressing the capsid protein of porcine circovirus type 2

Bacterial Expression of Antigenic Sites A and D in the Spike Protein of Transmissible Gastroenteritis Virus and Evaluation of Their Inhibitory Effects on Viral Infection

Adjuvant Domuz IL-12 ile Kombine Transmissible Gastroenteritis Virüs Spike Geni Taşıyan DNA Aşı Domuzlarda Bağışıklık Yanıtı İyileştirir

Genetic Fusions of Heat-Labile Toxoid (lt) and Heat-Stable Toxin B (stb) of Porcine Enterotoxigenic Escherichia Coli Elicit Protective Anti-Lt and Anti-Stb Antibodies

Immune Response of Mice Following Oral Inoculation of Recombinant Lactobacillus Expressing Porcine Transmissible Gastroenteritis Virus Spike Glycoprotein

Construction of a bivalent DNA vaccine co-expressing S genes of transmissible gastroenteritis virus and porcine epidemic diarrhea virus delivered by attenuated Salmonella typhimurium